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Early-Stage Dementia
Diagnosis and Care
Dementia caused by Alzheimer's
disease and other factors is taking a
tremendous toll on elders and their
families. However, if the disease is
diagnosed and treated early, many
patients can avoid or delay secondary
medical and social complications.
By Victor G. Valcour, M.D. and
. Patricia L. Blanchette, M.D.
Dr. Victor G. Valcour is an Assistant Professor of
Medicine of the Department of Geriatric Medicine at
the John A. Burns School of Medicine, University of
Hawaii in Honolulu. His main research interest is
dementia recognition.
Dr. Patricia L. Blanchette is Professor and Chair of the
Department of Geriatric Medicine, John A. Burns
School of Medicine, University of Hawaii. She is also
the President of the Hawaii state chapter of the
Alzheimer's Association and a member of the national
board of the Alzheimer's Association.
n 1907, a German clinician, Alois Alzheimer,
first described symptoms of a disease charac-
terized by progressive and unrelentingJ1 ! memory loss that correlated with marked de-
creased brain size at autopsy.' The disease
was described as a presenile illness and considered
relatively rare. Now, with the exception of relatively
uncommon familial forms, it is acknowledged to be
primarily an illness of the aged.
In the United States, the prevalence of dementia
in those aged sixty-five or greater is five to ten per-
cent, the majority of which is caused by Alzheimer's
disease. The virtual epidemic of the disease is related
to the fact that from age sixty to eighty-five there is
a doubling of dementia prevalence every five years,
until at age eighty-five, the disease prevalence is be-
tween thirty to fifty percent.2 Dementia has also been
found to exist in every country where it has been
seriously studied and where the population survives
into old age. It affects an estimated four million
people in the United States.3 Between 2010 and 2050,
the number of people with Alzheimer's will increase
from about five and a half million to fourteen mil-
lion, as the baby boomers enter the age of highest
risk. Worldwide, dementia is a leading cause of mor-
bidity, affecting more than fifteen million people. 4
While research has yielded a great deal of knowl-
edge about the pathophysiology of this illness, to this
day dementia is, by and large, incurable.
At least half of individuals who live to eighty-
five years of age maintain normal memory and
thinking. However, with a prevalence of some form
of dementia as high as fifty percent at age eighty-
five, many incorrectly accept dementia as a normal
part of aging. While dementia may be common, it is
definitely not to be considered an inevitable conse-
quence of aging.
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Some other forms of dementia, such as that due
to stroke or brain trauma, may be easier to think
about as preventable or treatable. However, current
research in Alzheimer's disease holds out promise for
the discovery of modifiable risk factors and disease-
modifying treatment. With increasing numbers of
people living into old age, the devastation it causes
in the lives of individuals and families, and the costs
of care, dictate that the disease be approached ag-
gressively for prevention, treatment, and cure. A
significant barrier is failure to make a diagnosis early
in the course of illness, which leads to preventable
secondary medical and social complications.
This article will review significant aspects of early
dementia diagnosis and treatment. It will concen-
trate on the importance of early diagnosis with
respect to education for patients and families, safety
issues, and providing patients with an opportunity
for self-determination prior to the loss of decision-
making capacity.
Definition of Dementia and Mild
Cognitive Impairment
Definition and Staging of Dementia
Dementia is a clinical diagnosis made using defined
criteria based on standards of normative adult
cognitive performance. While there are several sets
of defined criteria, the Diagnostic and Statistical
Manual of Mental Disorders is most commonly ref-
erenced (DSM-IV).s Findings required for a DSM-IV
criteria-based diagnosis include the presence of ac-
quired memory impairment, either in short-term
memory or long-term memory, and an abnormality
of one other area of cognitive function, such as ab-
straction, visuospatial skills, attention, language,
judgment, insight, or personality. The diagnostic
requirement for the deficits to be acquired is in-
tended to distinguish the diagnosis of dementia from
that of developmental disability and congenital
abnormalities.
The evaluation must also assess for reversible
situations, such as the use of mind-altering substances
(e.g. medications or alcohol), which if eliminated,
could reverse the abnormalities. These situations are
typically marked by acute or subacute deficits in at-
tention, a condition termed delirium. It is difficult
to make a diagnosis of dementia with confidence in
individuals who have a delirium. This can be a par-
ticularly difficult issue given a predilection for
delirium to occur in individuals with dementia.6
When delirium is superimposed, it can make the
dementia symptoms markedly worse in a short pe-
riod of time. Depression is another underdiagnosed
common condition that can cause reversible deficits
in cognition.7
Dementia is typically staged as mild, moderate,
or advanced. Standardized criteria are used in re-
search-however, clinical acumen is typically the
basis for staging in medical practice. Mild disease is
characterized by continued ability to function in most
daily activities, limited by a mild and often unrecog-
nized decrease in memory and thinking ability. This
memory deficit is often described as "forgetfulness."
In a social context, one can often continue to func-
tion without significant problems, thus making the
diagnosis more difficult and recognition by family
members delayed.8
As an individual progresses to the moderate stage
of dementia, forgetfulness is more apparent and be-
havioral issues may arise including getting lost in
familiar surroundings, asking the same questions over
and over, or developing psychotic symptoms such as
paranoid delusions or hallucinations. In this stage, fam-
ily members often seek medical attention for the patient
mainly because of problem behavior and compromised
judgment. Patients themselves often lack insight into
their disease and may deny symptoms. At this point, it
is typically more difficult for patients to weigh the ben-
efits and risks of their decisions.
In advanced disease, patients have difficulty with
daily activities and usually require twenty-four-hour
assistance and supervision. People with dementia
often have disrupted sleep patterns, making their care
more difficult for family caregivers. Bowel and blad-
der habits may become disrupted, which can lead to
incontinence. The stress of providing constant
twenty-four-hour supervision and disturbed night-
time sleep often result in significant health risks for
family caregivers, who often seek institutional place-
ment for the patient.9
The loss of capacity to make competent decisions
is a uniform finding in advanced disease. In very
advanced disease, patients typically lose most com-
munication skills and are unable to complete simple
tasks such as feeding and toileting themselves.
Types of Dementia
The terms "Alzheimer's" and "dementia" are often
used interchangeably, yet Alzheimer's disease is only
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one of several conditions that cause dementia.
Dementia is a term that encompasses a number of
diseases characterized by cognitive decline. The con-
fusion between these terms may stem from the high
prevalence of Alzheimer's disease, the most common
type of dementia in the United States. As a single
process, it accounts for more than half of all reported
dementia cases.10 In people of European descent,
Alzheimer's disease is more commonly the etiology
of the dementia than among people of Asian descent,
where hypertensive stroke-related dementia is more
prevalent than in whites.11 The actual prevalence of
various types of dementia in any given population is
related to various factors, including genetic inherit-
ance of the disease or a predisposition to it, and the
prevalence of hypertension and stroke.
Several other diseases lead to dementia and are
important with regard to early detection and treat-
ment. Of these conditions, vascular dementia is the
most common. In this disorder, there is a compro-
mise of the vascular supply to the brain. Examples
include the vascular occlusion or intracranial bleed-
ing that occurs with stroke, either large-vessel stroke
that may be clinically apparent, or small-vessel stroke
that may go unnoticed until there is an accumula-
tion of multiple small strokes leading to changes in
personality and problems with memory and think-
ing. To a trained clinician, there are salient differences
in the presentation, clinical findings, and disease
course that can distinguish vascular dementia from
Alzheimer's disease. To a friend or family member
of a person afflicted, however, the distinctions can
be unclear and the disease course can appear fairly
similar. In some series, vascular dementia accounts
for as much as thirty percent of dementia cases and
is a contributing factor to an additional twenty-one
percent. 12
Pertinent to the early diagnosis and treatment of
dementia are a number of conditions or diseases that
cause cognitive impairment and can be corrected or
improved if discovered early.13 Some of these include
metabolic abnormalities such as abnormally low or
high thyroid function, excess alcohol consumption,
and vitamin B12 deficiency. Infections (neuro-
syphilis), dysfunction in flow of cerebrospinal fluid
as seen in normal-pressure hydrocephalus (NPH), un-
detected seizure disorder, and a subdural hematoma
(SDH), are other possible reversible conditions that
can lead to cognitive decline. Early detection of dis-
ease and medical assessment for reversible etiologies
is the mainstay to reversing or improving symptoms
related to these conditions. 14
Definition of Mild Cognitive Impairment
Mild cognitive impairment (MCI) is a relatively new
term used to describe subtle changes in memory and
thinking at a level that is not sufficiently impaired to
meet diagnostic criteria for dementia."5 While defi-
nitions for MCI have varied, they generally include
a subjective complaint of memory problem with some
objective evidence of decline in ability to think or
remember. Data on outcomes for persons with this
diagnosis are limited. As many as half of the people
with MCI have been found to progressively worsen
to the point where a diagnosis of dementia is made.16
When more strict criteria are used, the percentage of
individuals who progress to dementia is somewhat
greater, approaching one hundred percent. 7 Never-
theless, it appears that dementia is not a uniform
outcome. As such, MCI can be viewed as a signifi-
cant risk factor for dementia. It is currently the
earliest stage in which individuals could be defined
as at risk for developing dementia and has therefore
become an increasingly important target for research
in disease-modifying treatments.
It is useful to think of the term "dementia" to
include a number of conditions and a range of sever-
ity, from minimal symptoms to advanced disease.
Seen in this light, it becomes apparent that an af-
flicted individual will eventually lose ability to
perform all tasks independently. It is equally appar-
ent that individuals with mild disease may initially
retain the ability to perform many tasks.
Individuals with dementia have variable degrees
of impairment in each domain of thinking; this pro-
vides heterogeneity in presentation and progression
of disease and makes it necessary to view all cases
individually. Given anticipated changes over time, it
is important to continually assess the ability to per-
form individual tasks. These are important concepts
to understand when considering issues of indepen-
dence, driving safety, decision-making ability, and
rights of self-determination.
Epidemiology of Dementia
An estimated five to ten percent of the U.S. popula-
tion is affected by a dementing disorder. 8 Advanced
age is by far the greatest risk factor for developing
dementia.As above, there is a doubling of the preva-
lence with every five years of advancing age from
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less than one percent for people less than sixty years
of age to a rate approaching fifty percent for people
over eighty-five. There are limited data on the most
aged elders, making it difficult to know the exact
prevalence of disease in this group.19 Given marked
association to advancing age and the increase in the
numbers of older persons, there is a great potential
for exponential growth in the numbers of persons
with dementia in the coming decades.
There are several factors that may impact upon
the changes in the prevalence of dementia, however.
For example, there is a growing body of evidence
that intellectual stimulation and maximal educational
attainment may delay time to onset of clinical symp-
toms of dementia. 20 There is not enough evidence as
yet to absolutely confirm this finding or define mag-
nitude of any effect. If it holds true, an impact leading
to a decreased prevalence could be seen, given that,
by and large, younger people are better educated than
the current generation of older people.
It is also possible that advances in treatment or
prevention will be made that will have a significant
impact on prevalence. For example, current treat-
ment options for Alzheimer's disease, including
cholinesterase inhibitors, can attenuate symptoms of
this disease for a period of time in some patients.21
These medications appear to work better when
started in the mild to moderate stages of the disease.
With better and earlier diagnosis and more effective
treatments, prevalence rates could be greatly im-
proved. Since there is a doubling of the disease every
five years after the age of sixty-five, treatment that
could delay the onset or slow the progression by five
years could result in reducing the prevalence by as
much as one-half. Because the mortality from many
other conditions also increases with advancing age,
any slowing of progression of dementia would lead
to a significant decline in the prevalence of moder-
ate and advanced disease. The social impact of a
decline in the prevalence of advanced dementia can-
not be overstated. As a rule, older people fear losing
their cognitive abilities more than they fear dying.
The cost of caring for people with dementia is
substantial. Several analyses have suggested the to-
tal direct (patient-care expenditures) and indirect
(unpaid in-home care) annual costs to care for a per-
son with Alzheimer's disease are $35,000 or greater.22
In 1991, minimum estimates of long-term dollar
losses to the U.S. economy due to Alzheimer's dis-
ease were $536 billion (direct) and $1.75 trillion
(total). 23 A study by the Lewin Group for the
Alzheimer's Association shows that within ten years,
the cost to Medicare of treating people with
Alzheimer's disease will soar from $31.9 billion in
2000 to $49.3 billion in 2010.24 The report shows a
similar impact on Medicaid, with program expendi-
tures for nursing-home care for people with
Alzheimer's disease increasing from $18.2 billion in
2000 to $49.3 billion in 2010.
These numbers highlight the substantial direct
costs involved, but there are also considerable indi-
rect costs, particularly the costs to caregivers who
miss work or leave jobs entirely to care for affected
family members.
Regardless of the changes in disease prevalence,
it is likely that the social and economic costs of
dementia care will remain significant. It is hoped that
advances in research will keep these costs from reach-
ing epidemic proportions.
Early Diagnosis of Dementia
The foundation of the medical profession lies in the
ability to prevent or detect medical illness and to
provide treatment to reduce suffering and early death.
In this capacity, the desire to cure is a driving force.
Because of the high prevalence of chronic diseases
for which no cure currently exists, the ability to cure
is reduced for physicians caring for older patients.
In contrast, there is often the potential for reducing
pain and suffering and delaying the complications
of these conditions, as seen with treatments for
osteoarthritis, congestive heart failure, and dementia.
While dementia cannot be cured, many of the
accompanying symptoms-such as depression, agi-
tation, sleep disturbances, and psychosis-can be
greatly improved with treatment. In addition,
caregivers can be greatly helped with counseling,
support, and referral to community resources and
support groups. This is best accomplished when dis-
ease is detected early; however, early detection often
does not occur.
The lack of curative pharmacological treatments
may be playing a role in explaining the current low
levels of clinical detection of dementia in its early stages.
Investigators have suggested this as an etiology, as well
as a need for better education of physicians in the de-
tection of mild disease. 2 In both community settings
and teaching hospitals, physician detection rates for
mild disease are less than fifty percent. 26 Family mem-
bers, as well, often overlook mild disease.27
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In contrast to limited pharmacological options,
there are a number of non-pharmacological inter-
ventions aimed at altering the consequences of
disease. Many of these interventions become less
applicable with advancing disease. Examples of these
interventions include providing patients with an op-
tion of self-determination through advanced
decision-making about healthcare, finances, and
other personal issues. Education of patients and
caregivers is important, as it can reduce worrying
and suffering for everyone involved. With early de-
tection and education, there is an opportunity to
prevent unsafe or abusive situations, such as patient
or caregiver abuse, financial abuse, wandering be-
havior, and medication noncompliance. It is
important to recognize the potential for these prob-
lems and to modify the environment to protect the
patient and reduce family stress and conflicts.
The hallmark of early detection is periodic cogni-
tive function testing for persons at risk. This is not
currently uniformly advocated. The United States Pre-
ventative Task Force (USPTF), which makes
recommendations to care providers concerning preven-
tion of disease, concludes that insufficient data exist to
recommend periodic cognitive testing.2 Among other
sources, it references the American College of
Physician's position recommending periodic evaluation
of function in older individuals and using these data to
determine who needs further testing. The Agency for
Health Care Policy and Research (now called
"AHCPR") of the U.S. Department of Health and
Human Services recommends watching for triggers that
would suggest the possible presence of a cognitive dis-
order and subsequently evaluating these individuals. 29
These triggers include activities such as missing appoint-
ments and forgetfulness-symptoms often overlooked
by caregivers and family members when the disease is
mild. It is not clear that this approach is sensitive enough
to detect mild (early) disease.
Further controversy exists concerning the age at
which to begin testing. While risk increases expo-
nentially with age, the exact age at which testing
becomes sensitive enough to do on a large scale has
not been determined. The value of any screening test
correlates directly to the prevalence of disease in a
population. If the prevalence is too low (younger age),
then the predictive value of the test decreases. On
the other hand, screening an older population, while
increasing predictive value, risks missing younger
persons with disease.
There is also controversy concerning the tests to
perform. All cognitive tests for screening must con-
sider the balance of time to administer and test
sensitivity. Tests with greater sensitivity typically re-
quire greater effort and time to complete, and thus
become prohibitive as a screening tool. Shorter tests
have less sensitivity.
A diagnosis of dementia is dependent upon docu-
mentation of decline in several areas of thinking,
including memory. Many interactive tests have been
developed to detect disease in patients. The most
formal of these is full neuropsychological testing,
which is prohibitively lengthy for routine clinical use
as a screening tool. Short portable tests have been
devised. The most common of these brief tests is the
Mini Mental State Exam (MMSE) designed by
Folstein and Folstein and first reported in 1975. 30
The MMSE is a brief test that can be performed
by any trained individual. It allows the participant
to obtain a maximum of 30 points. Questions are
heavily weighted on orientation (10 points), how-
ever several other domains of thinking are tested
including recent memory (3 points), language, at-
tention, and visuospatial skill. It has been well
validated and is probably the best known of the short
mental status tests. Normal ranges have been de-
scribed for various levels of education.3
The MMSE is not without limitation, however.
While it is quite easy to perform, variations in ad-
ministering the testing can lead to differing results.
Standardization through proper training is impor-
tant. The MMSE is a rather simple test, particularly
for well-educated individuals. As a result, well-edu-
cated people can still score 30 despite the presence
of cognitive decline from their baseline-so-called
"ceiling effects." The MMSE lacks evaluation of sev-
eral important domains of thinking, such as
personality, abstraction, and judgment.
Another common test used by clinicians is the
clock-drawing task.32 In this test, participants draw
a clock with all the numbers on it and subsequently
put the hands in the clock to indicate a designated
time. The tester is able to observe the participant
complete the tasks and assess several critical areas
of thinking, including visuospatial skill and execu-
tive function. It does not test memory directly and
serves better as a complement to a test such as the
MMSE.
There are a host of other tests available. They
are generally limited, however, by a lack of familiar-
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ity and thus portability (the ability of having the test
done reliably and consistently at a different location
and time). Sensitivity varies from test to test.
All short cognitive tests should be viewed as a
tool to assist in diagnosis. Appropriate diagnosis can
be made only through clinician evaluation.
Treatment Options
Treatment of early-stage dementia requires a com-
prehensive approach encompassing not only
traditional medical aspects of care, but also
psychosocial needs. The result can have a tremen-
dous impact on quality of life for an individual. There
are four distinct arms to the treatment of early-stage
dementia: education, opportunities for self-determi-
nation, safety, and medications.
Education
There is a remarkable degree of misconception sur-
rounding dementia, particularly Alzheimer's disease.
Patients and family members are often unaware that
these misconceptions exist. Older patients tend to
be less aggressive in asking questions concerning their
illness, and younger family members may be uncom-
fortable asking some questions, particularly
concerning heredity. The result can be a lack of in-
teraction concerning these issues and added burden
to the patient and family due to lack of information.
The burden to caregivers is substantial. Numer-
ous investigations have revealed higher rates of illness
in persons who care for others, including increased
depression, poorer quality of life, and increased
mortality.33 Caregivers of patients with dementia tend
to have a notably higher level of stress when com-
pared to caregivers of patients with other chronic
illnesses.3 4 Models of geriatric care, such as Geriat-
ric Evaluation and Management (GEM) units, have
shown a decreased burden through increased inter-
action with caregivers. 35
An important aspect of the education is a dis-
cussion concerning an anticipated course of the
illness. While many factors concerning dementia are
unknown, many aspects concerning the clinical
course are well understood, and others can be dis-
cussed in generality, providing practical information
for families and patients.
It is known, for example, that dementia is a
chronic, slowly progressive illness with a spectrum
of symptoms from mild disease (where little assis-
tance is needed) to advanced disease (where full
supportive care in all aspects of daily life is required).
While the exact course for each person varies, the
course tends to progress at a similar rate within in-
dividual cases. Individuals maintain an ability to
perform some tasks initially; however, this ability will
deteriorate as the disease progresses. This informa-
tion implies a need to continually assess the ability
to perform tasks and reset the ongoing balance be-
tween patient autonomy and safety for each
individual. Awareness of these pieces of information
allows caregivers to anticipate changes, prepare for
an increased need of assistance, and prevent unsafe
situations.
It is also known that some forms of dementia
carry a hereditary predisposition. Families are typi-
cally keenly interested in this information.
Fortunately, types of dementia with marked heredi-
tary predisposition are relatively rare. For example,
Alzheimer's disease does carry a hereditary compo-
nent for individuals who develop the disease early in
life (typically younger than sixty); however, the most
common type of Alzheimer's disease-occurring later
in life--carries a much lower degree of hereditary
predisposition, which is dwarfed by the risk of in-
creasing age.
Education to patients and family members should
include information about advance directives and
safety. A referral to a caregiver support group is a
valuable means to increase knowledge and provide
a mechanism for ongoing family support.
Advance Directives/Self Determination/
Decision-Making Capacity
The spectrum of decision-making capacity associated
with dementia is wide and ever-changing for each
individual. In early stages, patients typically main-
tain the ability to make decisions appropriately. With
early detection of illness, we can provide individuals
with an opportunity to indicate their values and
wishes through the use of advance directives.
A challenge for medical and legal professionals
is to define the point at which one loses this deci-
sion-making ability. Evaluation is necessary to
balance societal needs to protect an individual from
harm while maximizing patient autonomy. An im-
portant consideration for the clinician in entering
into an assessment of capacity--especially when fi-
nancial matters are involved-regards receiving the
appropriate authority to do the assessment. That
is, the patient must understand the reason for the
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assessment, or an attorney representing the interests
of the patient must be involved. Without such an
attorney as the patient's agent, the clinician may in-
advertently enter into a process that is intended to
deprive the patient of assets without the patient's
interests being protected. Prior to the beginning of
the assessment, the clinician is well advised to ob-
tain absolute assurance that the patient's rights are
being protected. Having written confirmation from
an attorney that represents the patient is an excel-
lent way of proceeding.
Decision-making capacity is dependent upon the
level of cognition required for specific decisions. This
issue has been called "specific capacity." For ex-
ample, patients may maintain an ability to make
simple decisions long after they lose the ability to
make more difficult decisions. They may be able to
designate a surrogate for healthcare decisions long
after they have lost the ability to understand medi-
cal or financial procedures.
Decision-making capacity should be distin-
guished from competence. While determination of
competence is a decision of the courts, capacity re-
fers to the ability to perform a particular task, such
as making or revoking a will, deciding on a course
of treatment, or completing advance directives.
Physicians are often called upon to provide an
opinion regarding capacity when caring for individu-
als with dementia. As above, physicians should assure
themselves that the patients' rights are being pro-
tected. The basic components of determining
decision-making capacity include an evaluation of a
patient's ability to understand the question or issue
at hand, to understand and weigh the risks and ben-
efits of the decision, to recognize alternatives, to make
a reasoned decision, and to communicate that deci-
sion to the evaluator.3 6 It is helpful to assess the
continuity of the final decision with previously ex-
pressed values.
Patients should be able to express in their own
words both the question at hand and the decision
they make. This is particularly important when medi-
cal interventions are being addressed. A common
practice for constructing informed-consent forms for
medical research, for example, involves using a level
of language complexity equivalent to that of the mean
years of education for those intended to be enrolled,
typically around an eighth-grade education level. This
avoids the use of more technical jargon and maxi-
mizes the degree to which individuals can understand
aspects of the decision. The same is true in weighing
risks and benefits of an intervention. An individual
should be able to express these risks and benefits in
his or her own words. Simple repetition of what the
evaluator says can be an indication of lack of under-
standing and should be probed for clarity.
The setting of the evaluation should be a consid-
eration. The individual should be relaxed and
comfortable. An assessment for transient conditions,
such as intoxication or use of medications that can
alter thinking, should be a prerequisite. Confidenti-
ality should be maintained for the individual, and
the evaluator should ensure that communication is
not an issue, as might occur with language and dia-
lect barriers.
In early-stage dementia, patients typically main-
tain the ability to make many decisions. It is an
appropriate time to address advance directives that
help to direct future patient care before decision-
making capacity no longer exists. This can be done
formally through a living will and a durable power
of attorney for healthcare decisions. In some states,
a doctor's note in the medical record can serve as a
legal advance directive. State laws vary, and clini-
cians should inform themselves of the laws in their
states before counseling a patient about advance
directives.
Safety Awareness, Including Driver Safety
One of the most significant interventions in the care
of early-stage dementia is initiating mechanisms to
evaluate and maintain safety. Through deterioration
of thinking processes, individuals lose the capability
to protect themselves from harm. Examples of com-
mon unsafe practices include forgetting to turn off a
stove, leaving water running, overpaying or under-
paying bills, wandering into traffic, getting lost, or
being taken advantage of financially by overly zeal-
ous door-to-door salespersons or telemarketers.
Unsupervised access to large amounts of cash or to
valuable possessions can make a person with early
dementia a target for violence and abuse. Directed
interventions, such as monitoring checkbooks or
limiting maximum deductions from financial ac-
counts, can help protect assets. Other simple
interventions include monitoring cooking and house-
hold tasks.
It is often beneficial to obtain an identification
bracelet with information regarding contact num-
bers of family members if the individual becomes
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lost. These are readily available through programs
such as the Alzheimer's Association's "Safe Return"
program or the Medic Alert program.
Another important intervention involves moni-
toring medication compliance and use of
over-the-counter remedies. This directive would aim
to decrease missed doses of medications or inadvert-
ent overdoses that occur when patients forget that
they have already taken their medications. It should
also aim to minimize use of over-the-counter medi-
cations that can transiently affect thinking ability.
Examples include sleeping medications, cold rem-
edies, and anti-diarrheal medications. Use of
pillboxes with daily slots for medications can be es-
pecially useful.
Driver safety is a particularly difficult issue to
address. Driving is a key element to independence
for most individuals and an activity that they do not
readily want to give up. Physicians may not want to
recommend taking away such an important func-
tion prematurely, and yet physician input is a
powerful tool toward driving cessation when war-
ranted. The assessment can be notably difficult in
that a diagnosis of dementia does not universally
imply an inability to drive safely when the disease is
mild.37 If the disease is advanced, however, driving is
clearly not safe. When a relative should stop driving
often becomes a heated debate for families.
State requirements for reporting differ. In some
states, reporting of individuals thought to be unsafe
is mandatory, while in other states, patient confi-
dentiality takes precedence and reporting cannot
occur without written consent from the patient. For-
mal evaluations of driving safety are available, but
are often costly and are not typically covered by
medical insurance. However, they are apt to be much
less costly than preventable automobile accidents.
Driving evaluations often include simulated tests,
road tests, or both. Unfortunately, however, the data
provided are quite limited as a result of the progres-
sive nature of the deterioration seen with dementia,
which can lead to loss of applicability in as little time
as six months.38 Therefore, there is a need to indi-
vidualize the decision with patients and their families,
with an aim to discontinue driving before a danger-
ous situation occurs, but to maximize function as
long as possible. The safest and easiest way to ac-
complish this involves early discussion and the
implementation of options for alternative transpor-
tation. Many communities have transportation
options for the elderly that are prepared to deal with
memory-impaired individuals.
Medical Therapeutics
Currently, there are several treatment options avail-
able for dementia, each with modest benefit, at best.
These treatments focus mainly on symptoms of the
disease without curing or halting the disease. How-
ever, the evidence is becoming clearer that the
medications may slow the progression of the disease,
an important cost consideration in terms of being
able to delay the need for twenty-four-hour supervi-
sion or institutional care.
The Food and Drug Administration (FDA) has
approved four medications in the class of acetyl cho-
linesterase inhibitor for the treatment of Alzheimer's
disease. These medications work on the central ner-
vous system to increase the local amount of
acetycholine, an important neurotransmitter for
memory and thinking. In clinical trials, these medi-
cations have shown a statistically significant
improvement in patients with disease, particularly
in evaluations of daily function. 39 While these changes
are statistically significant, they do not universally
translate into a clinically notable change for all indi-
viduals. The benefit in some may be marked more
by a delay in deterioration of thinking and improved
behavior rather than a noticeable improvement in
cognition. 40 Most of these medications are well tol-
erated when properly used; however, the cost is a
barrier for some patients.
A number of other medications have received
attention in the treatment of dementia. For individu-
als with a vascular etiology to their dementia, usually
small or large strokes, an assessment as to etiology
of the strokes-such as hypertension or cardiac
arrhythmia--can prevent further deterioration by
preventing future strokes. There is also evidence that
low-dose aspirin may decrease the rate of progres-
sion of some forms of this disease.4i
Several studies have looked at vitamin E use in
patients with dementia.42 While there appears to be
a benefit to its use, it is modest. The ideal dose has
not been established, and there is a potential for com-
plications (particularly bleeding) at high doses.
Equally unclear is the usefulness of ginkgo biloba,
an extract from a deciduous tree bearing the same
name. It is a well-known herbal preparation that has
been used for "cerebral vascular insufficiency." 43
Published, well-designed, double-blind studies are
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lacking, but one is currently underway. A high drop-
out rate and inability to ensure that persons in the
placebo group did not have access to the herb are
significant limitations to current published studies.44
There is a great deal of interest in the use of es-
trogen for the prevention of Alzheimer's disease. A
recent well-designed study evaluating estrogen as a
treatment for established Alzheimer's disease showed
no benefit.45 Whether estrogen provides a protective
effect on the development of Alzheimer's disease is
not resolved. Currently, available data are based on
cross-sectional study designs in which individuals
with and without dementia report their past estro-
gen use. Here, a suggestion of possible benefit is
found.46 However, this retrospective method is lim-
iting and does not provide a definitive answer.
Prospective studies, such as the Women's Health Ini-
tiative Memory Study, are underway to answer this
question.47
Epidemiological studies have indicated a possible
benefit of non-steroidal anti-inflammatory drugs
(NSAIDs), for delaying the onset of Alzheimer's dis-
ease.48 This may be important, or it may simply be a
statistical correlation without actual clinical benefit.
NSAIDs can cause gastrointestinal bleeding and re-
nal dysfunction, and they would need to be taken
over many years to provide preventive benefit. Again,
studies are underway to determine the risks and ben-
efits of NSAIDs in the prevention, delay, or treatment
of Alzheimer's disease.
Clearly, pharmacological therapy for the treat-
ment of the cognitive impairment in dementia is
limited, while there are significant numbers of non-
pharmacological interventions described. This
highlights the need for clinicians to address early-
stage dementia care in a comprehensive manner that
includes a discussion of psychosocial needs.
Future Trends
Although dementia is much better understood than
in the past, currently more questions than answers
remain. A considerable amount of research is ongo-
ing; however, given the personal and societal impact,
much more is required. Alzheimer's disease, vascu-
lar dementia, Parkinson's dementia, and other
dementias are age-related, but not age-inevitable,
diseases. The impact on individuals, families, and
society is tremendous.
Given the aging of the population, without ex-
tensive research into prevention and intervention, the
world is facing a medical and social crisis. However,
because of the marked increased risk for each half-
decade of life over sixty, delaying the onset of
Alzheimer's disease by even five years could result in
reducing by half the number of people who will be
affected.
A promising vaccine therapy in mice models
could have a tremendous impact on dementia care
and prevention in the future. 49 Discoveries about
preventable risk factors would be significant. It will
be critically important to determine whether estro-
gens, NSAIDs, gingko biloba, vitamins, or other
substances can actually delay-with an acceptable
level of safety-the development or progression of
Alzheimer's disease.
The success of disease intervention, now and in
the future, will depend upon the ability to detect
early-stage dementia, evaluate for confounding and
reversible conditions, and institute a comprehensive
plan aimed at treatment, prevention, and monitor-
ing.'This process involves not only healthcare
professionals, but also individuals from multiple dis-
ciplines, including family members, financial
advisors, and legal professionals.
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